Table 2. Patients with refractory DLBCL.
| DLBCLPatient | Sex | Age | COO | Treatment | Response | Status | Sample source | OS (months) | IZ IC50nM |
|---|---|---|---|---|---|---|---|---|---|
| PT-1 | M | 46.9 | Non-GCB | RICE, splenectomy | progression | Dead | Fluid | 6.5 | 59.2 |
| PT-2 | M | 82.5 | Non-GCB | R-CHOP | relapse and progression | Dead | PB | 13.5 | 57.9 |
| PT-3 | F | 48.2 | Non-GCB | R-ESHAP, hyper- CVAD, auto SCT | relapse and progression | Dead | Fluid | 14.8 | 35.9 |
| PT-4 | F | 75.6 | Non-GCB | R-CHOP, R-ESHAP, Rituxan+MTX +cytarabine, COPP, radiaRon, Revlimid | partial remission and progression | Dead | Apheresis | 40.7 | 122 |
| PT-5 | M | 55.5 | GCB | CHOP, hyper-CVAD, RICE, RDAP | relapse and progression | Dead | PB | 14.4 | 200 |
| PT-6 | M | 47.4 | Non-GCB | CHOP, DA-EPOCH, ICE, auto SCT, hyper- CVAD | partial remission and progression | Dead | Apheresis | 29.2 | 201 |
| PT-7 | M | 38.7 | GCB | R-CHOP, RICE | progression | Dead | Fluid | 8.2 | 132 |
| PT-8 | F | 69.0 | GCB | R-hyper-CVAD, R- EPOCH, RICE, ritumimab_revlimid | progression | Dead | Fluid | 49.3 | 60.8 |
| PT-9 | F | 68.2 | GCB | R-CHOP, R-GEMOX, benamusRne +rituximab | progression | Dead | Apheresis | 38.1 | 44.5 |
| PT-10 | M | 63.5 | GCB | R-CHOP, RICE, auto SCT, R-GEMOX | relapse and progression | Dead | PB | 10.2 | 75 |
Dx, diagnosis; COO, cell of origin; OS, overall survival; IZ, ixazomib; NA, not available; GCB, germinal center B cell; RICE: rituximab, ifosfamide, carboplatin, etopiside; VTEP, R-CHOP: rituximab-cyclophophamide, hydroxydaunorubicin, oncovin, prednisone; R-ESHAP: rituximab-etoposide, solu-medrol-methylprednisolone, high-dose Ara-C-cytarabine, platinol; CVAD: cyclophosphamide, vincristine, doxorubicin, dexamethasone; DA-EPOCH: dose adjusted-etoposide, prednisolone, oncovin, cyclophosphamide, hydroxydaunorubicin; R-GEMOX: rituximab-gemcitabine, oxaliplatin; SCT, stem cell transplant; PB, peripheral blood.